electroCore Aims Noninvasive Neurostimulation At The Masses

Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.